John Hart to Esophageal Neoplasms
This is a "connection" page, showing publications John Hart has written about Esophageal Neoplasms.
Connection Strength
1.032
-
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
Score: 0.137
-
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48.
Score: 0.111
-
Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One. 2014; 9(7):e100586.
Score: 0.088
-
Complete endoscopic mucosal resection is effective and durable treatment for Barrett's-associated neoplasia. Clin Gastroenterol Hepatol. 2014 Dec; 12(12):2002-10.e1-2.
Score: 0.087
-
Development of subsquamous cancer after hybrid endoscopic therapy for intramucosal Barrett's cancer. Endoscopy. 2012; 44 Suppl 2 UCTN:E390-1.
Score: 0.079
-
Evaluation of microvascular density in Barrett's associated neoplasia. Mod Pathol. 2013 Jan; 26(1):125-30.
Score: 0.078
-
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012 Aug; 143(2):336-46.
Score: 0.076
-
Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience. Am J Gastroenterol. 2009 Nov; 104(11):2684-92.
Score: 0.063
-
Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management. Gastrointest Endosc. 2009 Sep; 70(3):417-21.
Score: 0.062
-
Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol. 2008 Feb; 6(2):159-64.
Score: 0.056
-
Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy. 2007 Dec; 39(12):1086-91.
Score: 0.055
-
Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 2005 Apr 15; 65(8):3146-54.
Score: 0.047
-
Basaloid squamous cell carcinoma of the esophagus with or without adenoid cystic features. Arch Pathol Lab Med. 2004 Oct; 128(10):1124-30.
Score: 0.045
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.033
-
Confocal laser endomicroscopy: potential in the management of Barrett's esophagus. Dis Esophagus. 2010 Jul; 23(5):E21-31.
Score: 0.017